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BoronophenylalanineBackground and purpose: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a ther-
apeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment
of such patients and the factors associated with treatment response and survival.
Methods and materials: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with
L-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012.
Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumula-
tive dose of 66 Gy (interquartile range [IQR], 59–70 Gy) administered with or without concomitant
chemotherapy. Tumor response was assessed using the RECISTv.1.0 criteria.
Results: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2
treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57–79%) of the 69 evaluable
patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable dis-
ease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice
responded more often than those treated once. The median follow-up time after BNCT was 7.8 years.
The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high
minimum tumor dose and a small volume were independently associated with long survival in a multi-
variable analysis.
Conclusions: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive
for response and survival.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 137 (2019) 153–158
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Head and neck squamous cell carcinoma (HNSCC) can be cured
with surgery and radiotherapy with or without systemic therapy,
but locoregional recurrence is not uncommon. Cancers that recur
locally are often considered inoperable, and may pose a therapeu-
tic challenge, because reirradiation is often associated with sub-
stantial toxicity, and chemotherapy and immunotherapy have
limited efficacy in most patients [1,2]. Intensity modulated radio-
therapy (IMRT) and stereotactic radiotherapy (SRT) may allow
delivery of relatively high re-treatment radiation doses without
excessive adverse effects to the normal tissues and may improve
tumor local control rates in selected patients [3–10]. Young age,
a good performance status, a small gross tumor volume (GTV),
histology other than squamous cell carcinoma, nasopharyngeal,
oropharyngeal or laryngeal cancer location, and longer than a2-year time interval between the first and the second radiotherapy
courses are associated with favorable outcome after reirradiation
[6,8–10]. Yet, prognosis of patients with recurrent HNSCC remains
poor, and novel effective treatments are needed [8–9,11].
Boron neutron capture therapy (BNCT) is based on targeted
release of high-linear energy transfer (high-LET) particles within
cancerous tissue following boron (10B) neutron capture. In practice,
a boron carrier compound (for example, L-boronophenylalanine [L-
BPA]) is first infused into a peripheral vein, usually resulting in a
higher uptake of the 10B carrier in cancerous tissues as compared
with the normal tissues. The tumor is subsequently irradiated with
an external neutron beam with energy in the epithermal range
(0.5 eV < E < 10 keV), which leads to thermalization of the neutrons
in tissue, boron neutron capture, and fission of 10B to a-particles
and lithium-7 nuclei. Because 4He and 7Li have a high-LET and a
short range (<10 mm) in tissue, most of the absorbed dose is depos-
ited in cancer [12]. Therefore, a high dose gradient may be
achieved between cancerous and adjacent normal tissues provided
Table 1
Characteristics of patients and tumors, and treatments given.
Characteristic No. of
patients
(%) N = 79
Median
(IQR)
Age (y) 62 (54, 68)
Gender
Male 49 (62)
Female 30 (38)
Tumor site
Larynx 8 (10)
Maxillary sinus or paranasal cavity 8 (10)
Pharynx 22 (28)
Oral cavity 39 (49)
Neck 2 (3)
Primary treatment*
Surgery 56 (71)
Radiotherapy 75 (95)
Chemotherapy 43 (54)
No. of prior radiotherapy treatments
0 3 (4)
154 BNCT for recurrent head and neck cancerthat the boron carrier is selectively taken up by the tumor. Since
BNCT is a high-LET radiotherapy modality, it is often delivered in
a single fraction [13].
The relationships between the dose resulting from BNCT, tumor
response to BNCT, and survival are incompletely understood. The
maximum dose delivered from BNCT is usually limited by the tol-
erance of the adjacent critical tissues, particularly the oral and pha-
ryngeal mucosa when treating patients with HNSCC, whereas the
spinal cord is seldom the primary limiting radiosensitive organ.
The tumor and normal tissue doses are usually estimated based
on an average blood boron concentration at the time of neutron
irradiation assuming a constant tumor-to-the whole blood boron
concentration ratio [13,14]. In the present study we examined
the relationships between the estimated tumor dose from BNCT,
tumor volume, and treatment outcomes in a patient cohort with
inoperable locally recurrent HNSCC. To our knowledge, this is the
first study to investigate these relationships in this patient
population.1 65 (82)
2 10 (13)
Unknowny 1(1)
Cumulative target radiotherapy dose from
conventional radiotherapy
66 (59, 70)
Time from previous radiotherapy to BNCT (y) 1.1 (0.5, 2.4)
Gross tumor volume at the time of BNCT
(cm3)
105 (53,
187)
Tumor site at the time of BNCT
Upper esophagus 1 (1%)
Larynx 8 (10%)
Maxillary sinus or paranasal cavity 9 (11%)
Neck 7 (9)
Oral cavity 33 (42)
Pharynx 21 (27)
Abbreviations: IQR = interquartile range; BNCT = boron neutron capture therapy.
* 1 patient may have received more than 1 type of treatment.Materials and methods
Patient and tumor characteristics
Seventy-nine patients with HNSCC, who were treated with
BNCT at the FiR1 BNCT facility located in Espoo, Finland, between
February, 2003 and January, 2012, were included in the study
out of the total of 117 patients treated at this facility during this
time period. The study participants were required to have histolog-
ically verified HNSCC that had recurred locally and was considered
inoperable. We excluded patients with overt distant metastases,
patients who had the target tumor partly resected, and those
who interrupted neutron irradiation (Fig. 1).
Most patients (n = 75, 95%) had previously received radiother-
apy to the tumor site (Table 1). The most common sites of tumor
origin were the oral cavity and the pharynx. None of the patients
received any other cancer treatment concomitantly with BNCT.
When cancer progressed after BNCT, 23 patients received systemic
chemotherapy, 4 received radiotherapy to the primary tumor site
or a metastatic site, 7 underwent surgery, and 1 received gene
therapy. An institutional ethics board approved the study
(HUS/239/2017).Treatment administration
L-BPA was complexed with fructose to form L-BPA-fructose
(L-BPA-F) to increase solubility, and 350–400 mg/kg of L-BPA-FFig. 1. Patient accrual to the study. BNCT = boron neutron capturwas then administered intravenously at a concentration of 30 g/L
over a period of about 2 h before neutron irradiation at FiR 1, a
250-kW Triga Mark II nuclear research reactor (General Atomics,
San Diego, CA) [16–18]. Neutron irradiation was usually given from
2 portals (range, 1–3). Irradiation was started when the blood
boron concentration was approximately 20 mg/g, which occurred
79–104 (interquartile range, IQR) minutes after the end of L-BPA-
F infusion. Neutron irradiation lasted for a median of 42 minutes.
At the time of the first neutron field the median average blood
boron concentration, measured with inductively coupled plasma
atomic emission spectrometry [16], was 18 mg/g (IQR, 16–20 mg/g).e therapy; HNSCC = head and neck squamous cell carcinoma.
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The patients were followed up at 4-week to 12-week intervals
after BNCT. Clinical examination including pharyngolaryngoscopy
and medical imaging (magnetic resonance imaging [MRI], com-
puted tomography [CT], and/or positron emission tomography
[PET]) were used to detect cancer recurrence, and either CT, MRI,
or both were used to assess the tumor response. Treatment
response was evaluated according to the RECISTv.1.0 criteria
[15]. The minimum duration of stabile disease (SD) was defined
as 2 months as calculated from the date of the first BNCT to the
date of cancer progression.Dose calculation
Treatment planning and the Monte Carlo computation-based
dose calculation were performed with the software package SERA
(Simulation Environment for Radiotherapy Applications; Idaho
National Laboratory, Idaho Falls, ID) [17–19]. Four radiation dose
components were calculated: (1) the boron dose, the high-LET dose
resulting from the 10B(n,a)7Li reaction; (2) the nitrogen dose from
protons released in the thermal neutron capture reaction 14N(n,
p)14C in tissue; (3) the photon dose from the thermal neutron cap-
ture reaction of hydrogen 1H(n,c) in tissue and the minor photon
contamination in the neutron beam, and (4) the fast neutron dose
caused by protons released from the hydrogen recoil reaction 1H(n,
n0)p in tissue. The biological dose was derived as a sum of each
dose component multiplied with a constant weighting factor,
based on their relative biological effectiveness (RBE), except for
the boron dose, which was multiplied with a boron carrier-
specific compound effectiveness (CBE) factor [20]. The applied
weighting factors were 3.2 for the nitrogen dose and the fast neu-
tron dose, and 1.0 for the photon dose. For the boron dose, we
applied tissue-specific weighting factors, 3.8 for the tumor, 2.5
for the mucosal membranes, 2.5 for the skin, and 1.3 for the central
nervous system [13,22]. Tumor 18F-fluoro-L-BPA accumulation was
assessed prior to BNCT in 25 (32%) patients using PET yielding a
median tumor-to-background standardized uptake value (SUV) of
3.3. 18F-fluoro-L-BPA uptake results were not used in dose calcula-
tions. When biological doses are reported, the annotation ‘‘(W)’’ is
added after the dose for clarity.
The boron concentration in the tumor was estimated to be 3.5
times higher than in the whole blood during neutron irradiation,
and in the mucosal membranes 2 times higher. The mucosal mem-
branes have relatively high BPA uptake and are radiation sensitive
[13,21]. We limited the mucosal membrane absorbed physical dose
to 6 Gy for each BNCT treatment.Statistical analysis
Freedom from locoregional progression was defined as the time
from the date of the first BNCT to the date of detection of cancer
progression locoregionally. Patients who were alive without local
progression were censored on the date of the last contact, and
the patients who died without locoregional cancer progression
on the date of death. Overall survival (OS) was computed fromTable 2
Response to BNCT.
CR (n, %)
All evaluable patients, n = 69* 25 (36%)
BNCT given once, n = 31 6 (19%)
BNCT given twice, n = 38 19 (50%)
Abbreviation: CR = complete response; PR = partial response; SD = stable disease; PD = p
* 10 patients in the series were not evaluable for response.the date of the first BNCT to the date of death, censoring patients
who were lost to follow-up and those alive on last date of contact.
Binary logistic regression was used to identify factors that are
associated with achieving CR after BNCT (tested CR vs. PR, SD, or
progressive disease). Non-normal distributions between groups
were compared with the Mann–Whitney test or the Kruskal–Wal-
lis test. Frequency tables were analyzed with the chi-squared test.
Survival was analyzed using the Kaplan–Meier method, and sur-
vival between groups was compared with the log-rank test. A
Cox proportional hazard regression model was used to identify
covariables that are independently associated with survival.
Hazard ratios (HR) and their confidence intervals (CI) were calcu-
lated with a univariable Cox model. All p values are 2-sided. Statis-
tical analyses were performed with an SPSS Statistics version
1.0.0.580 (IBM Corp., Armonk, NY).Results
Doses delivered
Forty (51%) of the 79 patients were treated with BNCT twice and
39 (49%) once. The patients were scheduled for 2 treatments
except for the first patient in the series. The second BNCT was
not given to the 38 remaining patients, because 7 had distant
metastases detected, the neutron source was not available
(n = 5), 5 died early, 5 had prolonged toxicity from the first BNCT,
3 had poor performance status, 3 refused further treatment, 2 were
lost to follow-up, 2 had infection, 1 had an allergic reaction during
the BPA infusion, 1 kidney failure, and 1 cancer progression. The
reason for cancelation of the second BNCT was not reported in 3
cases.
The median time interval between the 2 treatments was
6 weeks (IQR, 5–8 weeks). Eighteen patients had the second BNCT
delayed >6 weeks (mucosal toxicity, 12; poor performance status,
4; infection, 2). The median minimum GTV dose from the first
BNCT was 15 Gy (W) (IQR, 12–18 Gy [W]). For the 40 patients
who received only 1 BNCT, the median minimum tumor dose
was 14 Gy (W) (IQR, 10–16 Gy [W]), and in the subset of 39
patients who received 2 BNCT treatments, the median of the sum
of the minimum tumor doses from each treatment was 30 Gy
(W) (IQR, 26–34 Gy [W]). The median of the maximum physical
mucosa doses from single BNCT was 5.4 Gy (IQR, 4.9–5.9 Gy), cor-
responding to a biological dose of 11.9 Gy (W) (IQR, 10.5–12.9 Gy
[W]). An average of 92% of the biological tumor dose resulted from
the boron dose, 4% from the photon dose, 3% from the nitrogen
dose, and 1% from the fast neutron dose.Response to BNCT
Ten (13%) patients were not evaluable for response (8 died
within 2 months from date of BNCT, 2 were lost to follow-up;
Table 2). SD lasted for a median of 4.2 months (range, 2.2–
19.2 months). The objective response rate (a CR or a PR) was 68%
(47/69 patients; 95% CI, 57–79%; Fig. 2; Supplementary Fig. 1).
The evaluable patients treated twice with BNCT responded
more often than the patients treated once (29/37 [78%] vs. 18/32PR (n, %) SD (n, %) PD (n, %)
22 (32%) 17 (25%) 5 (7%)
11 (36%) 10 (32%) 4 (13%)
11 (29%) 7 (18%) 1 (3%)
rogressive disease; BNCT = boron neutron capture therapy.
Fig 2. A 62-year-old woman with a local recurrence of tongue cancer growing into the floor of the mount after surgery and radiotherapy. An MRI prior to BNCT (A), 3 months
after BNCT (B), and 2 years after BNCT showing a complete response (C).
156 BNCT for recurrent head and neck cancer[56%], respectively; p = 0.049). A high minimum tumor dose from
the first BNCT was predictive for achieving CR (p = 0.038). Patients
who achieved CR had a median minimum tumor dose of 17 Gy (W)Fig. 3. Overall survival (A), overall survival in the subgroups of patients who received a m
survival in the subgroups of patients who received a minimum GTV dose of 18 Gy
progression. The censored patients are indicated with a bar. The 2-year and 10-year surfrom the first BNCT treatment as compared with 14 Gy (W) among
the rest of the patients (p < 0.001). The GTV of the patients who
achieved CR was smaller than the GTV in the rest of the evaluableinimum GTV dose of 15 Gy (W) or >15 Gy (W) (more than the median; B), overall
(W) or >18 Gy (W) (the highest quartile; C), and (D) freedom from locoregional
vival rates are shown.
Table 3
Multivariable Cox regression hazard model for overall survival.
Covariable* Hazard ratio (95% CI) p
Gross tumor volume (cm3) 1.003 (1.001–1.005) 0.007
Minimum dose from the first BNCT (Gy [W]) 0.941 (0.891–0.994) 0.030
Time from prior photon irradiation
to the date of BNCT (years)
1.030 (0.934–1.136) 0.557
Abbreviations: CI = Confidence interval; BNCT = boron neutron capture therapy.
* The covariables were entered as continuous factors into the model.
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p < 0.001). Twenty-two (81%) of the 27 patients who had a GTV
smaller than the median (<105 cm3) and who received a minimum
tumor dose higher than the median (>15 Gy [W]) responded (had
CR or PR). Neither age at the time of BNCT (tested < median
[62 years] vs. > median; p = 0.680) nor the length of the time inter-
val from prior photon irradiation to the date of BNCT (median
[1.1 years] vs. >median; p = 0.097) was associated with response.Overall survival
Three patients were alive without head and neck cancer 5.5, 7.8,
and 10.3 years after the date of BNCT. The median OS was
10 months, and 2-year OS was 21% (Fig. 3).
A GTV size smaller than the median (105 cm3, p = 0.001), a
minimum tumor dose higher than the median minimum tumor
dose from the first BNCT (15 Gy [W], p = 0.021), a minimum tumor
dose in the highest quartile (>18 Gy [W], p < 0.001), and a time
longer than the median time (1.1 years) from prior photon radio-
therapy to the date of BNCT (p = 0.004) were identified as factors
associated with favorable OS in univariable survival analyses,
whereas gender, age (tested median vs. >median), the primary
tumor site, the number of BNCT treatments given (1 vs. 2), and
the time between stopping L-BPA-F infusion and starting neutron
irradiation (median [91 minutes] vs. >median) were not signifi-
cantly associated with OS in univariable analyses (p > 0.05 for each
analysis). The minimum tumor dose in the highest quartile (>18 Gy
[W]) from the first BNCT had the strongest association with OS. Of
the patients who received a dose >18 Gy (W), 46% survived for
2 years after BNCT as compared with 12% of those who received
a smaller dose (Fig. 3, panel C).Multivariable analysis of overall survival
To find out which of the factors examined were independently
associated with OS, we entered the factors that were significantly
associated with OS in a univariable analysis into a Cox multivari-
able model. A small GTV size and a high minimum tumor dose
from the first BNCT were independently associated with OS,
whereas the time interval between prior photon irradiation and
the date of BNCT were not (Table 3). As a sensitivity analysis, we
entered the number of BNCT treatments given (1 or 2) as the fourth
covariable into the model, but the results remained essentially
unaltered. When the minimum GTV dose resulting from the first
BNCT treatment was replaced with the sum of the minimum GTV
doses in those cases when 2 BNCT treatments were given as a
covariable in the model, the GTV size was the only significant fac-
tor associated with survival (HR 1.003, 95% CI 1.001–1.005,
p = 0.001).Locoregional tumor control
The median time without locoregional cancer progression was
9 months, and 35% of the patients were free from locoregional pro-gression 2 years after BNCT (Fig. 3). A GTV smaller than the median
and a minimum tumor dose from the first BNCT in the highest
quartile were significantly associated with freedom from locore-
gional progression in univariable survival analyses (p = 0.032 and
0.007, respectively). A minimum tumor dose from the first BNCT
higher than the median tended to be associated with a long time
to locoregional progression (p = 0.095), whereas age, gender, tumor
site, and the number of BNCT treatments given were not (p > 0.05
for each analysis). When the tumor size and the minimum tumor
dose from the first BNCT treatment were entered into a Cox multi-
variable model as continuous variables, a high minimum tumor
dose from the first BNCT was significantly associated with a long
time to locoregional progression (HR 0.911, 95% CI 0.842–0.986,
p = 0.021), whereas tumor size was not (p = 0.451).Discussion
We found that most (68%) patients with inoperable, locally
recurrent, and previously irradiated HNSCC responded to BNCT,
and the 2-year OS was 21%. Importantly, the data suggest that a
high minimum dose delivered to the tumor from the first BNCT
is a key predictive factor for absence of locoregional progression
and OS, whereas the number of BNCT treatments given (either 1
or 2) may be a less important factor. To our knowledge, a similar
study has not been conducted earlier, and the current patient
cohort is the largest series with inoperable locally recurrent HNSCC
treated with BNCT reported to date.
In an agreement with the present findings, tumor size and the
radiation dose are also prognostic when patients with inoperable
recurrent HNSCC are re-irradiated with photons [7,9]. Of note,
most of the tumors we treated with BNCT were large (median
GTV size, 105 cm3) as compared with some series where recurrent
HNSCC was treated with conventional radiotherapy using SRT or
IMRT (median GTV size, 19–30 cm3) [3,7,9], and where tumor size
<25 cm3 was identified a favorable prognostic factor for survival
and achieving a CR [7,9]. In the present series, only 8/79 (10%)
patients had tumor volume <25 cm3. Interestingly, all 8 patients
responded to BNCT (CR, 7; PR, 1), and had a median OS of
25 months.
The minimum GTV dose of 18 Gy (W) (the highest quartile
dose) was associated with the best survival rates. This finding
may be supported by the observations done with conventional
photon irradiation using SRT. In one study [9] a dose >35 Gy deliv-
ered with SRT in 5 fractions to a small (<25 cm3) volume was asso-
ciated with favorable survival, which dose corresponds to a single
fraction dose of 18 Gy as calculated with linear quadratic equa-
tion using a/b = 10, but drawing firm conclusions is challenging
due to the differences between the studies and the potential biases
involved.
The current results appear to be in line with the results
obtained by others when evaluating BNCT as a treatment for head
and neck cancer, although the series differ and the data are scarce.
In a study consisting of 62 patients with either newly diagnosed
inoperable head and neck cancer or recurrent cancer the response
rate to BNCT was 58%, median OS 10 months, and the 2-year OS
rate 24% [23]. The median minimum tumor dose delivered was
17.9 Gy (W), the tumor volumes were not reported. In another ser-
ies where 17 patients with recurrent inoperable head and neck car-
cinoma or sarcoma were treated with BNCT twice, 12 (71%)
patients responded, 2-year OS was 47%, and the 2-year locore-
gional control rate 28%. In this study, the median tumor volume
was 15.6 cm3 and the minimum tumor dose from the first BNCT
13 Gy (W) [24].
The retrospective nature is a limitation of the current study.
Therefore, the response evaluations and follow-up schedules were
158 BNCT for recurrent head and neck cancerdone as per the institutional guidelines. The patient population
may be considered representative, since we included all patients
treated with BNCT in the center during the time period who ful-
filled the study inclusion criteria. The tumors were not tested rou-
tinely for human papilloma virus infection, since this was not the
norm at the time when the patients were treated, and, therefore,
these data are not available to us. The adverse effects related to
BNCT were not the topic of the present study, but, in general, they
resemble those of conventional radiotherapy, the most common
acute severe (grade 3) adverse effects consisting of oral mucositis,
oral pain, and fatigue [17,18]. No treatment-related deaths were
recorded.
The main disadvantages of BNCT have been insufficient dose to
deep-seated targets and the dependency on nuclear reactors as the
neutron source. The former limitation may be improved with novel
10B carriers, and the latter with accelerator-based neutron sources
that have recently become available for hospital installations
[25,26]. BNCT might be applicable also as a booster treatment to
conventional radiotherapy [27,28] or be combined with systemic
cancer therapies. Randomized trials comparing BNCT with other
radiotherapy modalities have not been carried out, but are needed
for the positioning of BNCT in the treatment armamentarium of
patients with head and neck cancer.
In summary, most patients with locally recurrent HNSCC
respond to L-boronophenylalanine-mediated BNCT despite prior
conventional radiotherapy in their history. A high minimum tumor
dose from BNCT is associated with a high response rate, a longer
time to locoregional progression after BNCT, and survival.Funding
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